Friday, 6 November 2026European Markets

How We Source Explore Search

#Chemicals

8 articles

Dow and Union Pacific Answer an Energy Shock with Cost Cuts and Cash, Not Growth Bets

Dow and Union Pacific Answer an Energy Shock with Cost Cuts and Cash, Not Growth Bets

LM Salvado•Oct 25, 2026

SOLVAC NOM(RETAIL) And SOLVAY Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Sep 29, 2024

SOLVAY, SOLVAC NOM(RETAIL), Another 1 Companies Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Feb 14, 2024

SOLVAC NOM(RETAIL) And ROBERTET CI Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Dec 3, 2023

SOLVAC NOM(RETAIL), SOLVAY, Another 2 Companies Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Dec 1, 2023

SOLVAC NOM(RETAIL), SOLVAY, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Mar 11, 2023

SOLVAY And ROBERTET Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Mar 10, 2023

SOLVAC NOM(RETAIL) And ROBERTET Have A High Dividend Yield And Return On Equity In The Chemicals Industry.

ViaNews Editorial Team (Europe)•Mar 9, 2023

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves

Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,549 source documents archived

Query this data → isubstrate.com